Clinical trial · Observational
Testosterone, Cognition, Ageing, and Cancer
Testosterone, Cognition, Ageing, and Cancer - A Controlled, Prospective Study About the Association Between Testosterone and the Prevalence and Severity of Cancer Related Cognitive Impairment in Testicular and Prostate Cancer Patients.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary aim of the study is - in a prospective controlled design - to examine whether treatment-induced decreases in testosterone acts as a mechanism of cancer-related cognitive impairment (CRCI) in testicular and prostate cancer patients. Secondary aims are 1) to explore whether decreases in testosterone interacts with increasing age to cause more severe CRCI in older patients, 2) to explore underlying neurophysiological (brain morphology) mechanisms of CRCI, and 3) to evaluate selected genetic variants as possible moderators of CRCI.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer-related Cognitive Impairment | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (3)
- label
- Testicular cancer patients
- description
- Forty testicular cancer patients included after orchiectomy but prior to any further treatment.
- label
- Prostate cancer patients
- description
- Forty prostate cancer patients included prior to medical castration and radiotherapy.
- label
- Healthy controls
- description
- Forty age- and education-matched healthy controls (20 matched to testicular cancer patients, 20 matched to prostate cancer patients).
Primary outcomes (1)
- measure
- Global cognitive functioning
- timeFrame
- Baseline and 6 months' follow-up
- description
- Changes in global cognitive composite score as measured with neuropsychological tests specified under "Secondary Outcome Measures".
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Confirmed diagnosis of testicular cancer * Confirmed diagnosis of prostate cancer and prescription of medical castration and radiotherapy Exclusion Criteria: * Previous cancer disease * Previous central nervous system disease * Brain metastases * Severe psychiatric disease (e.g., schizophrenia, major depressive disorder) * Insufficient Danish proficiency for neuropsychological testing
References
Publications (0)
Data not yet available